Zevra Therapeutics (ZVRA) Cash from Operations Growth (3y) (2017 - 2026)
Zevra Therapeutics (ZVRA) Cash from Operations Growth (3y) (2017 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash from Ops. Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
788,338.31 Bn |
788,338.28 Bn |
- |
- |
| 2 |
Belite Bio |
56,560.00 Bn |
56,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,329.30 Bn |
17,329.30 Bn |
- |
- |
| 4 |
Legend Biotech |
3,341.00 Bn |
3,340.71 Bn |
242.10 Mn |
37.40% |
| 5 |
Akari Therapeutics |
1,727.91 Bn |
1,727.91 Bn |
- |
20.11% |
| 6 |
Evaxion A |
1,536.68 Bn |
1,536.67 Bn |
- |
- |
| 7 |
Psyence Biomedical |
238.34 Bn |
238.33 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
113.42 Bn |
106.17 Bn |
2.59 Bn |
16.64% |
| 9 |
Abivax |
95.45 Bn |
95.45 Bn |
- |
- |
| 10 |
Zevra Therapeutics |
796.95 Mn |
596.33 Mn |
34.30 Mn |
52.10% |
| Date | Value |
|---|
| Mar 31, 2026 |
52.10% |
| Dec 31, 2025 |
47.92% |
| Sep 30, 2025 |
39.48% |
| Jun 30, 2025 |
4.26% |
| Mar 31, 2025 |
-32.27% |
| Dec 31, 2024 |
-167.60% |
| Sep 30, 2024 |
-88.00% |
| Jun 30, 2024 |
-46.60% |
| Mar 31, 2024 |
-84.21% |
| Dec 31, 2023 |
-148.03% |
| Sep 30, 2023 |
-63.91% |
| Jun 30, 2023 |
-81.40% |
| Mar 31, 2023 |
-26.00% |
| Dec 31, 2022 |
-12.93% |
| Sep 30, 2022 |
-43.58% |
| Jun 30, 2022 |
17.63% |
| Mar 31, 2022 |
31.52% |
| Dec 31, 2021 |
61.62% |
| Sep 30, 2021 |
44.48% |
| Jun 30, 2021 |
56.24% |
